Pain Therapeutics公 PTIE 深 沪
已收盘 10-02 16:00:00 美东时间
1.24
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.24
- 总市值 2066.00万
- 52周最高 2.99
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.76
- 委 比 0.00%
- 总股本 1666.13万
- 历史最高 43.54
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.76
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
Houston-based Plus Therapeutics subsidiary CNSide Diagnostics will launch its CSF assay platform for detecting cancer metastases in the central nervous system in Texas in August 2025. The initial commercial focus will be on NCI-Designated Cancer Centers and large healthcare systems. The CNSide assay offers high sensitivity (92%) and specificity (95%), surpassing traditional CSF cytology methods. It has been used in over 11,000 tests since 2020 an...
07-31 11:30
Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference
HOUSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, will present two studies at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, in Baltimore, MD. The studies focus on the clinical utility of the CNSide CSF Assay Platform for detecting and quantifying tumor cells in cerebrospinal fluid (CSF) in patients with leptomeningeal disease. Priya Kumthekar, M.D., will ...
07-10 11:30
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
Plus Therapeutics, Inc. will commercially launch its CNSide CSF Assay Platform for diagnosing CNS metastases in the U.S. in late 2025, targeting a $6+ billion underserved market. The platform, which offers superior sensitivity (92%) and specificity (95%) compared to traditional methods, has been used in over 11,000 tests since 2020. The company plans rapid expansion across the U.S. and has secured payor agreements. Management will host a conferen...
06-26 11:30
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Plus Therapeutics announced FDA clearance for its IND application for REYOBIQ™, a targeted radiotherapeutic, in a Phase 1/2a clinical trial for pediatric patients with recurrent, refractory, or progressive high-grade glioma and ependymoma. The trial, named ReSPECT-PBC, is funded by a $3.0M grant from the U.S. Department of Defense. The study aims to determine the maximum tolerated dose and assess safety, tolerability, and efficacy. REYOBIQ™ lever...
06-25 11:30
Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing
Plus Therapeutics announced a restructuring of its March 2025 $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares, enhancing shareholder value and simplifying its capital structure. Key changes include canceling dilutive warrants, removing 25 million shares of common stock, and using 90% of future proceeds to repay March 2025 financing holders at 115% of their original investment. The company also withdrew the...
06-24 11:30
疼死了有多疼？疼痛指数如何推动了癌症治疗？
本文来自微信公众号：CC情报局 （ID：cancer-weekly），作者：陈颀（德克萨斯大学奥斯汀分校社会工作博士生），原文标题：《疼死了有多疼？发明疼痛指数...
2022-07-07 16:18
在中国麻醉周 认识这群“生命的守护神”
■文/廖宏龙 通讯员：诸胜涛 指导医生：嘉兴市第一医院麻醉手术部副主任、主任医师 陆雅萍 特别采访：嘉兴市第一医院院长、浙北麻醉学区域专病中心主任...
2022-03-30 06:36
深耕疼痛治疗领域创新药物研发 熙源安健完成亿元级天使轮融资
据投资界报道，熙源安健医药(上海)有限公司(下称：熙源安健)宣布完成亿元级天使轮融资，由启明创投和博远资本共同领投，健壹资本跟投。 据公开资料显示，熙源安健是一...
2022-03-28 10:21
熙源安健宣布完成亿元级天使轮融资，启明创投、博远资本共同领投
投资界（ID：pedaily2012）3月28日消息，日前，疼痛治疗领域创新药物研发新锐企业熙源安健医药（上海）有限公司（下称“熙源安健”）正式宣布完成亿元级天...
2022-03-28 08:19
市第一医院疼痛治疗技术迈上新台阶
近日，市第一医院疼痛科开展了首例半月神经节脉冲射频神经调控治疗三叉神经眼支带状疱疹神经痛手术，有效解除了困扰患者的剧烈疼痛，取得了满意的临床效果。此次手术的成功...
2022-03-14 12:00
